OYST NASDAQ
Oyster Point Pharma, Inc.
1W: +0.0%
1M: -0.1%
3M: +98.8%
1Y: -41.1%
3Y: -54.3%
$11.17
Last traded 2022-12-30 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.0M
52W Range3.46-13.45
Volume2,088,283
Avg Volume424,562
Beta0.00
Dividend—
Analyst Ratings
Company Info
CEOJeffrey Nau
Employees303
SectorHealthcare
IndustryBiotechnology
IPO Date2019-10-31
Websiteoysterpointrx.com
202 Carnegie Ctr Ste 109
Princeton, NJ 08540
US
Princeton, NJ 08540
US
16093829032
About Oyster Point Pharma, Inc.
As of January 3, 2023, Oyster Point Pharma, Inc. was acquired by Viatris Inc. Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| InvOpps GP IV, L.L.C | U-Tender | 1,850,818 | — | 2023-01-03 |
| Versant Venture Capi | U-Tender | 1,003,658 | $11.00 | 2023-01-03 |
| Versant Venture Capi | U-Tender | 1,003,658 | — | 2023-01-03 |
| Behbahani Ali | D-Return | 10,066 | — | 2023-01-03 |
| Behbahani Ali | D-Return | 5,199 | — | 2023-01-03 |